UCB opens new manufacturing site in China
Posted by
12-Mar-2014
At UCB, we are nothing if not global. Our commitment to bringing our medicines to patients in Asia is embodied by our new manufacturing site at Zhuhai, China.
Zhuhai, in Guangdong Province, is one of China’s special economic zones. Strategically located on the west bank of the Pearl River Estuary and the southern side of the Pearl River Delta it will, by 2016, be connected to Macau and Hongkong by the longest bridge in the world.
The new site was officially inaugurated at a ceremony on February 28 at which Zhuhai’s Vice Mayor, Ms Long Guangyan, was in attendance.
Zhuhai demonstrates our willingness to invest in emerging markets as well as our dedication to sustainable production.
The brand new facility is situated in the Zhuhai High-Tech Industrial Park, covering an area of 12,000m2 , and features heating, ventilation and air-conditioning (HVAC) systems which are 50% more efficient than standard.
At present, 80 employees work in Zhuhai and the factory currently performs bulk manufacturing and packaging for our cardiovascular and iron products. In future, it will package other medicines, including one of our key epilepsy drugs.
Our new Zhuhai plant promises to play a key role in UCB’s development in the region by delivering reliable high-quality products to a growing numbers of patients in China and South East Asia.
Zhuhai, in Guangdong Province, is one of China’s special economic zones. Strategically located on the west bank of the Pearl River Estuary and the southern side of the Pearl River Delta it will, by 2016, be connected to Macau and Hongkong by the longest bridge in the world.
The new site was officially inaugurated at a ceremony on February 28 at which Zhuhai’s Vice Mayor, Ms Long Guangyan, was in attendance.
Zhuhai demonstrates our willingness to invest in emerging markets as well as our dedication to sustainable production.
The brand new facility is situated in the Zhuhai High-Tech Industrial Park, covering an area of 12,000m2 , and features heating, ventilation and air-conditioning (HVAC) systems which are 50% more efficient than standard.
At present, 80 employees work in Zhuhai and the factory currently performs bulk manufacturing and packaging for our cardiovascular and iron products. In future, it will package other medicines, including one of our key epilepsy drugs.
Our new Zhuhai plant promises to play a key role in UCB’s development in the region by delivering reliable high-quality products to a growing numbers of patients in China and South East Asia.
Leave a Comment